1 R.L. Siegel, K.D. Miller, H.E. Fuchs, et al.Cancer statistics, 2022 CA A Cancer J Clin, 72 (1) (2022), pp. 7-33

2 L. de Leval, E.S. JaffeLymphoma classification Cancer J, 26 (3) (2020), pp. 176-185

3 E.N. Mugnaini, N. GhoshLymphoma Prim Care, 43 (4) (2016), pp. 661-675

4 S.M. AnsellHodgkin lymphoma: diagnosis and treatment Mayo Clin Proc, 90 (11) (2015), pp. 1574-1583

5 G. Opinto, C. Agostinelli, S. Ciavarella, et al.Hodgkin lymphoma: a special microenvironment J Clin Med, 10 (20) (2021), p. 4665

6 U.E. Höpken, A. RehmTargeting the tumor microenvironment of leukemia and lymphoma Trends Cancer, 5 (6) (2019), pp. 351-364

7 T. Wu, Y. DaiTumor microenvironment and therapeutic response Cancer Lett, 387 (2017), pp. 61-68

8 T.F. Gajewski, H. Schreiber, Y.X. FuInnate and adaptive immune cells in the tumor microenvironment Nat Immunol, 14 (10) (2013), pp. 1014-1022

9 C. Chiozzini, E. Olivetta, M. Sanchez, et al.Tumor cells endowed with professional antigen-presenting cell functions prime PBLs to generate antitumor CTLs J Mol Med, 97 (8) (2019), pp. 1139-1153

10 D. Dersh, J.D. Phelan, M.E. Gumina, et al.Genome-wide screens identify lineage- and tumor-specific genes modulating MHC-I- and MHC-II-restricted immunosurveillance of human lymphomas Immunity, 54 (1) (2021) 116–131.e10

11 T. Maruhashi, I.M. Okazaki, D. Sugiura, et al.LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII Nat Immunol, 19 (12) (2018), pp. 1415-1426

12 M.P. Chao, A.A. Alizadeh, C. Tang, et al.Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma Cell, 142 (5) (2010), pp. 699-713

13 S.M. AnsellThe highs and lows of immune-checkpoint blockade in lymphoma Cancer Immunol Res, 7 (5) (2019), pp. 696-700

14 H. M'Hidi, M.L. Thibult, B. Chetaille, et al.High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia Am J Clin Pathol, 132 (4) (2009), pp. 589-596

15 L. Quan, X. Lan, Y. Meng, et al.BTLA marks a less cytotoxic T-cell subset in diffuse large B-cell lymphoma with high expression of checkpoints Exp Hematol, 60 (2018), pp. 47-56.e1

16 Y. Chen, M. Li, J. Cao, et al.CTLA-4 promotes lymphoma progression through tumor stem cell enrichment and immunosuppression Open Life Sci, 16 (1) (2021), pp. 909-919

17 T.W. Farren, J. Giustiniani, F.T. Liu, et al.Differential and tumor-specific expression of CD160 in B-cell malignancies Blood, 118 (8) (2011), pp. 2174-2183

18 P. Serafini, S. Mgebroff, K. Noonan, et al.Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells Cancer Res, 68 (13) (2008), pp. 5439-5449

19 S. Jaiswal, C.H.M. Jamieson, W.W. Pang, et al.CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis Cell, 138 (2) (2009), pp. 271-285

20 S.B. Willingham, J.P. Volkmer, A.J. Gentles, et al.The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors Proc Natl Acad Sci U S A, 109 (17) (2012), pp. 6662-6667

21 M.P. Chao, A.A. Alizadeh, C. Tang, et al.Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia Cancer Res, 71 (4) (2011), pp. 1374-1384

22 E. Brown, L. Hooper, T. Ho, et al.Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins J Cell Biol, 111 (6 Pt 1) (1990), pp. 2785-2794

23 M.I. Reinhold, F.P. Lindberg, D. Plas, et al.In vivo expression of alternatively spliced forms of integrin-associated protein (CD47) J Cell Sci, 108 (Pt 11) (1995), pp. 3419-3425

24 E.J. Brown, W.A. FrazierIntegrin-associated protein (CD47) and its ligands Trends Cell Biol, 11 (3) (2001), pp. 130-135

25 K. Ghimire, Y. Li, T. Chiba, et al.CD47 promotes age-associated deterioration in angiogenesis, blood flow and glucose homeostasis Cells, 9 (7) (2020), p. 1695

26 T. Hu, H. Liu, Z. Liang, et al.Tumor-intrinsic CD47 signal regulates glycolysis and promotes colorectal cancer cell growth and metastasis Theranostics, 10 (9) (2020), pp. 4056-4072

27 Y. Liu, Y. Chang, X. He, et al.CD47 enhances cell viability and migration ability but inhibits apoptosis in endometrial carcinoma cells via the PI3K/Akt/mTOR signaling pathway Front Oncol, 10 (2020), p. 1525

28 C.Y. Huang, Z.H. Ye, M.Y. Huang, et al.Regulation of CD47 expression in cancer cells Transl Oncol, 13 (12) (2020), Article 100862

29 M. Seiffert, C. Cant, Z. Chen, et al.Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47 Blood, 94 (11) (1999), pp. 3633-3643

30 U. LorenzSHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels Immunol Rev, 228 (1) (2009), pp. 342-359

31 Y. Fujioka, T. Matozaki, T. Noguchi, et al.A novel membrane glycoprotein, SHPS-1, that binds the SH2-domain-containing protein tyrosine phosphatase SHP-2 in response to mitogens and cell adhesion Mol Cell Biol, 16 (12) (1996), pp. 6887-6899

32 D. Pei, U. Lorenz, U. Klingmüller, et al.Intramolecular regulation of protein tyrosine phosphatase SH-PTP1:a new function for Src homology 2 domains Biochemistry, 33 (51) (1994), pp. 15483-15493

33 H. Liénard, P. Bruhns, O. Malbec, et al.Signal regulatory proteins negatively regulate immunoreceptor-dependent cell activation J Biol Chem, 274 (45) (1999), pp. 32493-32499

34 A.N. Barclay, T.K. Van den BergThe interaction between signal regulatory protein alpha (SIRPα) and CD47:structure, function, and therapeutic target Annu Rev Immunol, 32 (2014), pp. 25-50

35 M.E.W. Logtenberg, F.A. Scheeren, T.N. SchumacherThe CD47-SIRPα immune checkpoint Immunity, 52 (5) (2020), pp. 742-752

36 P.A. Oldenborg, H.D. Gresham, F.P. LindbergCD47-signal regulatory protein alpha (SIRPα) regulates Fcgamma and complement receptor-mediated phagocytosis J Exp Med, 193 (7) (2001), pp. 855-862

37 D. Tseng, J.P. Volkmer, S.B. Willingham, et al.Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response Proc Natl Acad Sci U S A, 110 (27) (2013), pp. 11103-11108

38 Y. Kikuchi, S. Uno, Y. Kinoshita, et al.Apoptosis inducing bivalent single-chain antibody fragments against CD47 showed antitumor potency for multiple myeloma Leuk Res, 29 (4) (2005), pp. 445-450

39 H. Zhang, H. Lu, L. Xiang, et al.HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells Proc Natl Acad Sci U S A, 112 (45) (2015), pp. E6215-E6223

40 D.M. Weiner, J.S. Durgin, M. Wysocka, et al.The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: current and future approaches J Am Acad Dermatol, 84 (3) (2021), pp. 597-604

41 W. Zhang, Y. Fan, M. Li, et al.Therapy strategy of CD47 in diffuse large B-cell lymphoma (DLBCL) Dis Markers, 2021 (2021), Article 4894022

42 B. López-Pereira, A.A. Fernández-Velasco, I. Fernández-Vega, et al.Expression of CD47 antigen in Reed-Sternberg cells as a new potential biomarker for classical Hodgkin lymphoma Clin Transl Oncol, 22 (5) (2020), pp. 782-785

43 A.F. HerreraNoncellular immune therapies for non-Hodgkin lymphoma Hematol Oncol Clin N Am, 33 (4) (2019), pp. 707-725

44 The Non-Hodgkin’s Lymphoma Classification ProjectA clinical evaluation of the international lymphoma study group classification of non-Hodgkin’s lymphoma Blood, 89 (11) (1997), pp. 3909-3918

45 A. Phan, R. Veldman, M.J. LechowiczT-cell lymphoma epidemiology: the known and unknown Curr Hematol Malig Rep, 11 (6) (2016), pp. 492-503

46 E. Tse, Y.L. KwongThe diagnosis and management of NK/T-cell lymphomas J Hematol Oncol, 10 (2017), p. 85

47 S. Jain, A. Van Scoyk, E.A. Morgan, et al.Targeted inhibition of CD47-SIRPα requires Fc-FcγR interactions to maximize activity in T-cell lymphomas Blood, 134 (17) (2019), pp. 1430-1440

48 K. Yang, J. Xu, Q. Liu, et al.Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia Pathol Res Pract, 215 (2) (2019), pp. 265-271

49 H. Kamijo, T. Miyagaki, N. Takahashi-Shishido, et al.Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47 Leukemia, 34 (3) (2020), pp. 845-856

50 J. Zhang, S. Jin, X. Guo, et al.Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy J Int Med Res, 46 (11) (2018), pp. 4418-4426

51 M.P. Chao, C. Tang, R.K. Pachynski, et al.Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy Blood, 118 (18) (2011), pp. 4890-4901

52 R. Bouwstra, Y. He, J. de Boer, et al.CD47 expression defines efficacy of rituximab with CHOP in non-germinal center B-cell (non-GCB) diffuse large B-cell lymphoma patients (DLBCL), but not in GCB DLBCL Cancer Immunol Res, 7 (10) (2019), pp. 1663-1671

53 R.K. Narla, H. Modi, D. Bauer, et al.Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody Cancer Immunol Immunother, 71 (2) (2022), pp. 473-489

54 Y. Huang, Y. Ma, P. Gao, et al.Targeting CD47:the achievements and concerns of current studies on cancer immunotherapy J Thorac Dis, 9 (2) (2017), pp. E168-E174

55 J. Liu, L. Wang, F. Zhao, et al.Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential PLoS One, 10 (9) (2015), Article e0137345

56 R. Advani, I. Flinn, L. Popplewell, et al.CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma N Engl J Med, 379 (18) (2018), pp. 1711-1721

57 B.I. Sikic, N. Lakhani, A. Patnaik, et al.First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers J Clin Oncol, 37 (12) (2019), pp. 946-953

58 V. Mateo, L. Lagneaux, D. Bron, et al.CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia Nat Med, 5 (11) (1999), pp. 1277-1284

59 V. Mateo, E.J. Brown, G. Biron, et al.Mechanisms of CD47-induced caspase-independent cell death in normal and leukemic cells: link between phosphatidylserine exposure and cytoskeleton organization Blood, 100 (8) (2002), pp. 2882-2890

60 H. Ni, L. Cao, Z. Wu, et al.Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody Cancer Immunol Immunother, 71 (2) (2022), pp. 353-363

61 M.O. Peluso, A. Adam, C.M. Armet, et al.The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a J Immunother Cancer, 8 (1) (2020), Article e000413

62 B. Oronsky, C. Carter, T. Reid, et al.Just eat it: a review of CD47 and SIRP-α antagonism Semin Oncol, 47 (2–3) (2020), pp. 117-124

63 M. Sagawa, T. Shimizu, N. Fukushima, et al.A new disulfide-linked dimer of a single-chain antibody fragment against human CD47 induces apoptosis in lymphoid malignant cells via the hypoxia inducible factor-1α pathway Cancer Sci, 102 (6) (2011), pp. 1208-1215

64 J. Qi, J. Li, B. Jiang, et al.A phase I/IIa study of lemzoparlimab, a monoclonal antibody targeting CD47, in patients with relapsed and/or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS):initial phase I results Blood, 136 (Supplement 1) (2020), pp. 30-31

65 M. Li, H. Yu, F. Qi, et al.Anti-CD47 immunotherapy in combination with BCL-2 inhibitor to enhance anti-tumor activity in B-cell lymphoma Hematol Oncol, 40 (4) (2022), pp. 596-608

66 A. Mehta, W. Harb, C. Xu, et al.Lemzoparlimab, a differentiated anti-CD47 antibody in combination with rituximab in relapsed and refractory non-Hodgkin’s lymphoma: initial clinical results Blood, 138 (Supplement 1) (2021), p. 3542

67 E.C. Piccione, S. Juarez, J. Liu, et al.A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells mAbs, 7 (5) (2015), pp. 946-956

68 W. Tian, S. Li, D. Chen, et al.Abstract 545:Preclinical development of a bispecific antibody-trap selectively targeting CD47 and CD20 for the treatment of B cell lineage cancer Cancer Res, 79 (13_Supplement) (2019), p. 545

69 L. Ma, M. Zhu, J. Gai, et al.Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential J Nanobiotechnol, 18 (2020), p. 12

70 Y. Wang, H. Ni, S. Zhou, et al.Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity Cancer Immunol Immunother, 70 (2) (2021), pp. 365-376

71 H. Zhang, M. Deng, P. Lin, et al.Frontiers and opportunities: highlights of the 2nd annual conference of the Chinese antibody society Antib Ther, 1 (2) (2018), pp. 65-74

72 Y. Wang, D. Pan, C. Huang, et al.Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibody mAbs, 12 (1) (2020), Article 1748322

73 A. Roohullah, V. Ganju, F. Zhang, et al.First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies J Clin Oncol, 39 (15_suppl) (2021), p. 2517

74 V. Buatois, Z. Johnson, S. Salgado-Pires, et al.Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B-cell lymphoma and leukemia Mol Cancer Therapeut, 17 (8) (2018), pp. 1739-1751

75 X. Chauchet, L. Cons, L. Chatel, et al.CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model Exp Hematol Oncol, 11 (2022), p. 26

76 K. Weiskopf, A.M. Ring, C.C. Ho, et al.Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies Science, 341 (6141) (2013), pp. 88-91

77 F.A. Harding, M.M. Stickler, J. Razo, et al.The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions mAbs, 2 (3) (2010), pp. 256-265

78 J. Yu, Y. Song, W. TianHow to select IgG subclasses in developing anti-tumor therapeutic antibodies J Hematol Oncol, 13 (2020), p. 45

79 G. Dekkers, A.E.H. Bentlage, T.C. Stegmann, et al.Affinity of human IgG subclasses to mouse Fc gamma receptors mAbs, 9 (5) (2017), pp. 767-773

80 K. Weiskopf, K.L. Anderson, D. Ito, et al.Eradication of canine diffuse large B-cell lymphoma in a murine xenograft model with CD47 blockade and anti-CD20 Cancer Immunol Res, 4 (12) (2016), pp. 1072-1087

81 A.R. Jalil, J.C. Andrechak, D.E. DischerMacrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure-function Antib Ther, 3 (2) (2020), pp. 80-94

82 R. Uger, L. JohnsonBlockade of the CD47-SIRPα axis: a promising approach for cancer immunotherapy Expet Opin Biol Ther, 20 (1) (2020), pp. 5-8

83 S.M. Ansell, M.B. Maris, A.M. Lesokhin, et al.Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies Clin Cancer Res, 27 (8) (2021), pp. 2190-2199

84 L.D.S. Johnson, S. Banerjee, O. Kruglov, et al.Targeting CD47 in Sézary syndrome with SIRPαFc Blood Adv, 3 (7) (2019), pp. 1145-1153

85 A. Russ, A.B. Hua, W.R. Montfort, et al.Blocking “don't eat me” signal of CD47-SIRPα in hematological malignancies, an in-depth review Blood Rev, 32 (6) (2018), pp. 480-489

86 Z. Jiang, H. Sun, J. Yu, et al.Targeting CD47 for cancer immunotherapy J Hematol Oncol, 14 (2021), p. 180

87 M. Billerhart, M. Schönhofer, H. Schueffl, et al.CD47-targeted cancer immunogene therapy: secreted SIRPα-Fc fusion protein eradicates tumors by macrophage and NK cell activation Mol Ther Oncolytics, 23 (2021), pp. 192-204

88 W. Li, S.K. Gupta, W. Han, et al.Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors J Hematol Oncol, 12 (2019), p. 73

89 H. Kamijo, M. Sugaya, N. Takahashi, et al.BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines Arch Dermatol Res, 309 (6) (2017), pp. 491-497

90 B. Montico, C. Lapenta, M. Ravo, et al.Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy OncoImmunology, 6 (11) (2017), Article e1356964

91 H. Cynis, Rahfeld Ju, A. Stephan, et al.Isolation of an isoenzyme of human glutaminyl cyclase: retention in the Golgi complex suggests involvement in the protein maturation machinery J Mol Biol, 379 (5) (2008), pp. 966-980

92 A. Stephan, M. Wermann, A. von Bohlen, et al.Mammalian glutaminyl cyclases and their isoenzymes have identical enzymatic characteristics FEBS J, 276 (22) (2009), pp. 6522-6536

93 Z. Wu, L. Weng, T. Zhang, et al.Identification of Glutaminyl Cyclase isoenzyme isoQC as a regulator of SIRPα-CD47 axis Cell Res, 29 (6) (2019), pp. 502-505

94 M.E.W. Logtenberg, J.H.M. Jansen, M. Raaben, et al.Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy Nat Med, 25 (4) (2019), pp. 612-619

95 R. Barreira da Silva, R.M. Leitao, X. Pechuan-Jorge, et al.Loss of the intracellular enzyme QPCTL limits chemokine function and reshapes myeloid infiltration to augment tumor immunity Nat Immunol, 23 (4) (2022), pp. 568-580

96 K. Bresser, M.E.W. Logtenberg, M. Toebes, et al.QPCTL regulates macrophage and monocyte abundance and inflammatory signatures in the tumor microenvironment OncoImmunology, 11 (1) (2022), Article 2049486

97 Z. Li, X. Gu, D. Rao, et al.Luteolin promotes macrophage-mediated phagocytosis by inhibiting CD47 pyroglutamation Transl Oncol, 14 (8) (2021), Article 101129

98 D. Hazama, Y. Yin, Y. Murata, et al.Macrocyclic peptide-mediated blockade of the CD47-SIRPα interaction as a potential cancer immunotherapy Cell Chem Biol, 27 (9) (2020), pp. 1181-1191.e7